Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor plus HAART and R-SC-EPOCH versus R-EPOCH in HIV-associated diffuse large B-cell lymphoma
ChiCTR2200060407Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab, etoposide, prednisone, vincristine, cyclophosphamide and 1 more in diffuse large B-cell lymphoma (DLBCL), AIDS-associated lymphoma (ARL) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Objective remission rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
rituximabetoposideprednisonevincristinecyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)AIDS-associated lymphoma (ARL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2200060407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060407.